Natera, Inc. (NASDAQ:NTRA – Get Free Report) CFO Michael Burkes Brophy sold 1,372 shares of the company’s stock in a transaction that occurred on Friday, September 29th. The stock was sold at an average price of $45.98, for a total value of $63,084.56. Following the completion of the sale, the chief financial officer now owns […]
Natera, Inc. (NASDAQ:NTRA – Get Free Report) has earned an average rating of “Buy” from the six brokerages that are presently covering the stock, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating. The average 1 year price target among brokers that have issued a report on the stock in the […]
Public Sector Pension Investment Board acquired a new position in Natera, Inc. (NASDAQ:NTRA – Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 155,000 shares of the medical research company’s stock, valued at approximately $8,606,000. Public Sector Pension Investment Board owned 0.14% […]
Zevenbergen Capital Investments LLC purchased a new position in Natera, Inc. (NASDAQ:NTRA – Free Report) in the first quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 286,020 shares of the medical research company’s stock, valued at approximately $15,880,000. Zevenbergen Capital Investments LLC owned 0.25% of Natera at the end […]
Natera (NASDAQ:NTRA – Get Free Report) and Epigenomics (OTCMKTS:EPGNY – Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, valuation, risk and dividends. Profitability This table compares Natera and Epigenomics’ net margins, return […]